Arbutus Biopharma ABUS
Arbutus Biopharma reported $59.12 million net income for Q3 2026.
Arbutus Biopharma (ABUS) filed a 10-Q with the SEC on Nov 10, 2026, 7:34 am ET. Source: the filing on SEC EDGAR.
- Form
- 10-Q
- Filed
- Importance
- Major
- Accession
- 0001447028-26-000064
- Revenue of $299,000 for the three months ended Sep 30, 2026.
- Net income of $59.12 million for the three months ended Sep 30, 2026.
- Diluted EPS of $0.30 for the three months ended Sep 30, 2026.
- Cash and equivalents of $264.19 million as of Sep 30, 2026.
Written from the 10-Q on EDGAR. AI can make mistakes. Check the filing.
What changed since last quarter
7 new legal mentions
Compared with the 10-Q for the period ended Jun 30, 2026.
| This filing | Previous | Change vs prior 10-Q | |
|---|---|---|---|
| Revenue | $299K | $1.01M | −71% |
| Operating income and margin | −$10.49M · -3509.7% | −$5.96M · -588.2% | −76%, margin −2921.5 pts |
| Net income | $59.12M | −$5.14M | +1249% |
| Operating cash flow | $239.81M | −$6.02M | +4085% |
| Cash | $264.19M | $19.17M | +1278% |
New legal mentions (7)
- Fact discovery is ongoing and a final pretrial conference is scheduled for November 2027.
- In March 2026, the Company, along with Genevant Sciences GmbH and, solely for specified purposes, its parent company Genevant Sciences Ltd. (collectively, "Genevant," a related party), entered into a settlement agreement (the "Moderna Settlement Agreement") with Moderna, Inc. and ModernaTX, Inc. (together, "Moderna")…
- The Company received $178.4 million in July 2026 as its share of the Noncontingent Settlement Payment, which included reimbursement of the Company's litigation costs. +3 more paragraphs
- In March 2026, we, along with Genevant Sciences GmbH and, solely for specified purposes, its parent company Genevant Sciences Ltd. (collectively, Genevant, a related party), entered into a settlement agreement (the Moderna Settlement Agreement) with Moderna, Inc. and ModernaTX, Inc. (together, Moderna) to resolve all…
- In addition, Moderna is obligated to pay us and Genevant an additional aggregate contingent lump sum payment of $1.3 billion (the Contingent Settlement Payment) upon a ruling that is favorable to us and Genevant in a limited appeal related to 28 U.S.C. §1498 (§1498) that Moderna filed, as allowed under the Moderna… +1 more paragraph
- and 2 more in the filing